ATAZANAVIR SULFATE

Post-LOESM

atazanavir

ANDAORALCAPSULE
Approved
Feb 2022
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

HIV-1 antiretroviral drug [see Microbiology ( )].

Clinical Trials (5)

NCT05236738Phase 1Completed

A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions

Started May 2022
42 enrolled
Healthy Participants
NCT04459286Phase 2Terminated

The Nitazoxanide Plus Atazanavir for COVID-19 Study

Started Oct 2020
57 enrolled
Covid-19
NCT04263350Phase 1Completed

A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same Time

Started Feb 2020
34 enrolled
Healthy Participants
NCT02603107Phase 3Completed

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Started Nov 2015
578 enrolled
HIV-1 Infection
NCT02589158Phase 1Completed

SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat

Started Nov 2015
16 enrolled
HIV